ArticleBMC gastroenterology2026
Therapeutic potential of β-sitosterol in methotrexate-induced liver injury: association with STING and ERK-1 pathways.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMethotrexate (MTX) is a commonly used drug to treat various cancers and autoimmune disorders, but its clinical utility is often limited by hepatotoxicity. β-sitosterol is a bioactive phytosterol compound that is naturally present in various plant foods and exhibits multiple antioxidant, anticancer and immunomodulatory activities. It has not been fully explored for its potential protective effects against liver injury. This study investigated whether β-sitosterol is associated with reduced hepatic injury in a short-term MTX model.
methodsThe rats were arbitrarily assigned to three groups as control, MTX and MTX + β-sitosterol groups. A single intraperitoneal dose of MTX was used to induce liver toxicity, and animals subsequently received either β-sitosterol or vehicle by oral gavage once daily for ten days. Liver tissues were evaluated using semi-quantitative histopathological scoring. Plasma alanine transaminase (ALT) and malondialdehyde (MDA), as well as liver transforming growth factor-β (TGF-β), MDA, stimulator of interferon genes (STING) and extracellular signal-regulated kinase 1 (ERK-1) levels were measured.
resultsβ-sitosterol treatment was associated with lower plasma ALT and MDA levels compared with the MTX group. Hepatic TGF-β, MDA, STING and ERK-1 levels were also reduced in the MTX + β-sitosterol group. Histopathology showed attenuated hepatocyte necrosis, inflammatory infiltration and early fibrotic changes.
conclusionsβ-sitosterol was associated with reduced oxidative stress markers and lower hepatic TGF-β, STING and ERK-1 levels in this short-term MTX injury model. These findings suggest that β-sitosterol may have potential therapeutic value in mitigating MTX-related hepatotoxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.